ARTICLE | Clinical News
Peregrine reports preliminary Phase II data
January 9, 2001 8:00 AM UTC
PPHM said preliminary results from a U.S. Phase II trial of its Cotara radiolabeled chimeric tumor necrosis therapy (TNT) antibody showed a median time to tumor progression of about 14 weeks, represen...